Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
2.150
+0.040 (1.90%)
At close: Jan 22, 2026, 4:00 PM EST
2.120
-0.030 (-1.40%)
After-hours: Jan 22, 2026, 7:42 PM EST
Silexion Therapeutics Employees
As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$660,500
Market Cap
6.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 14 | - | - | 11 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLXN News
- 5 weeks ago - Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer - GlobeNewsWire
- 4 months ago - Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 months ago - Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data - Benzinga
- 4 months ago - Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering - GlobeNewsWire